在炎症性肠病中使用乌斯特基努马布的临床结果
Sirisha K Gara1,2,3, Prathima Guntipalli3, Sima Marzban3
1Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, USA.
Cureus
|November 13, 2023
概括
乌斯特基努马布有效治疗中度至严重的炎症性肠病 (IBD),包括克罗恩病和性结肠炎. 剂量升级改善了结果,并且具有成本效益,特别是对于其他生物疗法失败的患者.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠道疾病 (IBD),如克罗恩病 (CD) 和性结肠炎 (UC),导致显著的发病率,包括疼痛,腹和疲劳.
- IBD发病率在地理位置上有所不同,影响生活质量,往往需要超越皮质类固醇或免疫调节剂的先进疗法.
- 生物疗法对于管理中度至重度IBD至关重要,手术只适用于耐火病例.
研究的目的:
- 审查乌斯特基努马布在治疗成年人中度至重度IBD的疗效和安全性.
- 评估乌斯特基努马布剂量升级对IBD患者临床结果的影响.
- 评估乌斯特基努马布与其他生物药物相比的成本效益,特别是在以前治疗失败的患者中.
主要方法:
- 对过去10年内发表的研究进行了广泛的文献搜索.
- 专注于用ustekinumab治疗的IBD的成年患者 (>18岁).
- 对回顾性研究的分析,检查乌斯特基努马布剂量升级和比较有效性.
主要成果:
- 生物向IL-12和IL-23的乌斯特基努马布被FDA批准用于中度至重度IBD.
- 回顾性研究表明,每四周增加一次ustekinumab的剂量可以改善临床结果并减少疾病恶化.
- 乌斯特基努马布在IBD的诱导和维持治疗中都显示出有效性和安全性,并且在TNF-α抑制剂失败时似乎具有成本效益.
结论:
- 乌斯特基努马布是适度至重度IBD的有效和安全的生物治疗选择.
- 在在IBD管理中切换生物药物之前,应考虑增加乌斯特基努马布的剂量.
- 需要进行进一步的研究,以探索在IBD中使用ustekinumab的挑战和机遇.
关键词:
克罗恩病是什么疾病这就是IBD,IBD,IBD.炎症性肠病是一种炎症性肠病.介质蛋白-12 介质蛋白-12 的作用.介质氨基-12/23单克隆抗体和IBD.介质素-23和性结肠炎.性结肠炎是一种乌斯蒂基诺姆巴布 (乌斯蒂基诺姆巴布) 是更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Inflammatory Bowel Disease II: Crohn's Disease
259
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
259
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147


